Prevalence and Incidence of Optic Neuritis in Patients with Different Types of Uveitis

Abstract

Incidence and prevalence of ON among patients with intermediate, posterior and pan uveitis were comparable and higher than the rates in patients with anterior uveitis.

Trends in Optic Neuritis Incidence and Prevalence in the UK and Association With Systemic and Neurologic Disease

“…Our findings of 10-fold higher odds of previous scleritis among patients with ON compared with controls and 5-fold higher odds of previous uveitis and hazard of incident uveitis are consistent with a US database study (103 867 patients with uveitis, including 974 with ON). This study reported similar ON prevalence in anterior uveitis and the general population (120 per 100 000 population [0.6%]) but higher ON prevalence in intermediate (280 per 100 000 population), posterior (290 per 100 000 population), and panuveitis (380 per 100 000 population).…”

“…Our findings, of ten-fold higher odds of previous scleritis amongst ON patients than controls, and five-fold higher odds of previous uveitis, and hazard of incident uveitis, are consistent with a USA database study (103,867 uveitis patients, including 974 with ON). 8 This reported similar ON prevalence in anterior uveitis and the general population (0.6%, 120/100,000 people), but higher ON prevalence in intermediate (280/100,000), posterior (290/100,000) and pan-uveitis (380/100,000). MS cohort studies (France n=4300, 33 Turkey n=1702 34 ) similarly report uveitis, especially intermediate and panuveitis, in between 0.52% and 0.65% patients, preceding MS diagnosis in 46%, simultaneous in 18%, and following diagnosis in 36%.…”

“…anti-TNFα therapy). 5 ON also develops in conjunction with other ocular presentations, including uveitis, 7,8 and scleritis. 9 This study had two aims.…”

“…5 Optic neuritis also develops in the context of reactive, primary, and secondary vasculitides, infection, postinfectious autoimmune reactions (including with human coronavirus disease 2019 [COVID-19]), 6 recent vaccination, and medication (eg, anti-tumor necrosis factor α therapy). 5 In addition, ON develops in conjunction with other ocular presentations, including uveitis 7,8 and scleritis. 9 This study has 2 aims.…”

Safety and Efficacy of Adalimumab in Patients with Noninfectious Uveitis in an Ongoing Open-Label Study: VISUAL III

“…However, the observed rate is comparable to the background rate reported in patients with uveitis who were not exposed to adalimumab (Guo D, et al, manuscript in progress). 30 Furthermore, there is a known association between anterior and intermediate uveitis and demyelinating disorders 31e33 ; for example, an estimated 7% to 10% of patients with intermediate uveitis also have multiple sclerosis. 34,35 There were no significant changes from baseline for laboratory tests or vital signs (data not shown).…”